```html

Leishmaniasis – Comprehensive Medical Guide

Overview

Leishmaniasis is a group of parasitic diseases caused by protozoa of the genus Leishmania. The parasites are transmitted to humans through the bite of infected female sand‑flies (family Psychodidae). Three clinical forms are recognized:

• Cutaneous leishmaniasis (CL) – lesions on the skin.
• Mucocutaneous leishmaniasis (MCL) – skin lesions that spread to mucous membranes of the nose, mouth, or throat.
• Visceral leishmaniasis (VL) – also called kala‑azar – a systemic disease affecting internal organs such as the spleen, liver, and bone marrow.

The disease is considered “neglected” because it predominates in poor, rural populations of tropical and subtropical regions. According to the World Health Organization (WHO), an estimated 700,000–1 million new cases occur worldwide each year, with >90 % of cases reported from 10 countries, including Brazil, India, Sudan, Ethiopia, and Bangladesh [1]. VL is the most lethal form, causing up to 20 % mortality if untreated.

Symptoms

Cutaneous Leishmaniasis (CL)

• Small, painless papule at the bite site (usually 1–2 cm) that may develop into a nodule or ulcer.
• Ulcer with raised, indurated (firm) borders and a clean base, often on exposed skin (face, arms, legs).
• Healed lesions may leave depressed or raised scars.

Mucocutaneous Leishmaniasis (MCL)

• Initial cutaneous lesions as described above.
• Secondary involvement of the nasal or oral mucosa weeks to years later, causing:
  • Nasal obstruction or nosebleeds.
  • Destruction of the nasal septum, leading to a “saddle‑nose” deformity.
  • Ulcers in the mouth, gums, or throat, causing pain while eating.

Visceral Leishmaniasis (VL) – Kala‑azar

• Persistent high‑grade fever (often >2 weeks).
• Weight loss, loss of appetite, and severe fatigue.
• Enlarged spleen (splenomegaly) and liver (hepatomegaly).
• Pancytopenia – low counts of red cells, white cells, and platelets, leading to anemia, increased infections, and easy bruising.
• Hyperpigmented patches on the skin (post‑kala‑azar dermal leishmaniasis, PKDL) may appear months after treatment.

Children and immunocompromised patients (e.g., HIV‑positive) often present with more severe systemic symptoms and may have atypical manifestations.

Causes and Risk Factors

Leishmaniasis results from infection with Leishmania parasites that reside inside macrophages after being injected by sand‑fly saliva. Over 20 species cause human disease, and the clinical form depends on both parasite species and host immunity.

Key Risk Factors

• Geography: Living in or traveling to endemic regions (the “Old World” – Middle East, Africa, Asia; the “New World” – Central and South America).
• Environmental exposure: Rural or peri‑urban settings with sand‑fly habitats (dry forest, shrubland, caves, animal shelters).
• Occupational exposure: Farming, mining, military service, construction, or logging where exposure to sand‑fly bites is frequent.
• Socio‑economic factors: Poverty, malnutrition, and lack of housing improvements increase risk.
• Immunosuppression: HIV infection, organ transplantation, or use of immunosuppressive drugs heightens susceptibility and can reactivate latent infection.
• Age: Children under 5 are especially vulnerable to VL because of their developing immune systems.

Diagnosis

Accurate diagnosis combines clinical suspicion with laboratory confirmation. The choice of test varies by disease form.

Cutaneous & Mucocutaneous Forms

• Microscopy: Direct visualization of amastigotes (Leishman‑Donovan bodies) in skin‑scraping or biopsy material after Giemsa staining.
• Culture: Growing promastigotes in Novy–McNeal–Nicolle (NNN) medium; takes 1–2 weeks.
• Polymerase Chain Reaction (PCR): Highly sensitive and species‑specific; increasingly the preferred method.
• Serology (less useful for CL): Detects antibodies but may be negative in localized disease.

Visceral Leishmaniasis

• Serologic tests: rK39 rapid immunochromatographic test and ELISA; sensitivity >90 % in endemic areas [2].
• Bone marrow, splenic or hepatic aspirate: Microscopy for amastigotes—gold standard but invasive.
• PCR on blood or tissue: Provides species identification and is useful when serology is equivocal.
• Complete blood count (CBC) and organ function labs: Reveal pancytopenia, elevated liver enzymes, and hypoalbuminemia.

Because clinical features overlap with other tropical infections (e.g., malaria, tuberculosis), a thorough travel and exposure history is essential.

Treatment Options

Treatment decisions are based on disease form, parasite species, geographic region, patient age, pregnancy status, and underlying health conditions.

First‑line Antimonial Compounds

• Sodium stibogluconate (SSG) – 20 mg/kg/day intravenously for 20–30 days (VL) or 10 days (CL). Effective but associated with cardiotoxicity, pancreatitis, and arthralgia.
• Meglumine antimoniate – Similar dosing; used where SSG resistance is low.

Liposomal Amphotericin B (AmBisome)

• Preferred for VL in the Indian subcontinent and East Africa due to high cure rates (>95 %) and lower toxicity.
• Dosing regimens vary: e.g., 3 mg/kg on days 1–5, 14, and 21 (total 21 mg/kg).

Miltefosine

• First oral agent for leishmaniasis; 2.5 mg/kg/day for 28 days (VL) or 3 weeks (CL).
• Contraindicated in pregnancy (teratogenic) and requires monitoring for gastrointestinal side effects.

Paromomycin

• Topical formulation for localized CL (5–10 % cream applied twice daily for 4–8 weeks).
• Injectable form (parenteral) used for VL in combination therapy.

Combination Therapies

In areas with high antimonial resistance, WHO recommends combining drugs (e.g., SSG + paromomycin, or liposomal amphotericin B + miltefosine) to improve efficacy and limit resistance development.

Supportive Care

• Blood transfusions for severe anemia.
• Platelet transfusion in cases of life‑threatening bleeding.
• Nutritional support and treatment of secondary bacterial infections.

Lifestyle & Adjunct Measures

• Good wound care for cutaneous lesions to prevent secondary infection.
• Hydration and rest during systemic illness.
• Avoidance of immunosuppressive drugs when possible; discuss alternatives with your physician.

Living with Leishmaniasis

Managing the disease after diagnosis involves medical follow‑up and daily self‑care practices.

General Tips

• Attend all scheduled appointments for medication monitoring and lab work.
• Maintain a balanced diet rich in protein, iron, and vitamins to support immune recovery.
• Keep a symptom diary (fever spikes, skin changes, bleeding) to report to your clinician.

Cutaneous Lesions

• Clean lesions gently with mild soap and water; pat dry.
• Apply prescribed topical antibiotics or antiseptic ointments to prevent bacterial superinfection.
• Protect healing skin from sun exposure—use broad‑spectrum sunscreen (SPF 30+) to reduce scarring.

Visceral Disease

• Monitor for signs of relapse (fever, fatigue, abdominal swelling) for at least 12 months after treatment.
• Vaccinate against preventable infections (e.g., influenza, pneumococcus) because of transient immunosuppression.
• Discuss family planning; some drugs (miltefosine) are teratogenic.

Psychosocial Support

Disfiguring skin lesions can cause anxiety and depression. Seek counseling, support groups, or community resources. Many NGOs in endemic regions provide psychosocial assistance.

Prevention

Because the parasite is vector‑borne, control strategies focus on reducing sand‑fly contact and reservoir hosts.

• Vector control: Insecticide‑treated bed nets (preferably with long‑lasting insecticidal nets, LLINs), indoor residual spraying, and environmental management (clearing vegetation, waste removal).
• Personal protection: Wear long‑sleeved shirts, long pants, and closed shoes during peak sand‑fly activity (dusk to dawn). Apply repellents containing DEET (20‑30 %) or picaridin.
• Housing improvements: Use screens on windows and doors; seal cracks in walls; plaster walls with cement to reduce sand‑fly resting sites.
• Reservoir control: In zoonotic areas, treat or cull infected dogs and rodents under veterinary guidance.
• Travel precautions: If traveling to endemic regions, obtain pre‑travel health advice, consider prophylactic measures, and avoid staying in poorly screened accommodations.

Complications

If left untreated or inadequately treated, leishmaniasis can lead to serious, sometimes fatal, complications.

• Visceral leishmaniasis: Progressive organ enlargement, severe anemia, hemorrhage, secondary bacterial infections, and death (mortality up to 20 % in untreated cases).
• Mucocutaneous disease: Destruction of nasal and oral structures leading to permanent disfigurement, chronic nasal obstruction, and difficulty swallowing.
• Secondary bacterial infection: Especially in ulcerated cutaneous lesions; can cause cellulitis or sepsis.
• Post‑kala‑azar dermal leishmaniasis (PKDL): Persistent skin rash after VL treatment; may serve as a reservoir for transmission.
• Drug toxicity: Antimonial agents can cause pancreatitis, cardiomyopathy, and renal impairment; amphotericin B may cause nephrotoxicity.

When to Seek Emergency Care

Call emergency services or go to the nearest hospital immediately if you experience any of the following:

• Severe, uncontrolled fever (>38.5 °C) lasting more than 48 hours.
• Rapid swelling of the abdomen or a feeling of fullness due to an enlarged spleen or liver.
• Significant bleeding (e.g., vomit blood, heavy nosebleeds, or blood in urine/stool).
• Sudden drop in blood pressure, dizziness, or fainting.
• Severe shortness of breath or chest pain.
• Uncontrolled pain or rapidly spreading infection around a skin lesion.
• Signs of severe anemia (pale skin, rapid heartbeat, extreme fatigue) or thrombocytopenia (easy bruising, petechiae).

These symptoms may indicate life‑threatening complications of visceral leishmaniasis or severe drug reactions. Prompt medical attention can be lifesaving.

---

References:

1. World Health Organization. Leishmaniasis. 2022. https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
2. Centers for Disease Control and Prevention. Leishmaniasis – Diagnosis. 2023. https://www.cdc.gov/parasites/leishmaniasis/diagnosis.html
3. Mayo Clinic. Visceral leishmaniasis (kala‑azar). 2023. https://www.mayoclinic.org/diseases-conditions/visceral-leishmaniasis/symptoms-causes/syc-20354057
4. Cleveland Clinic. Cutaneous Leishmaniasis. 2022. https://my.clevelandclinic.org/health/diseases/22127-cutaneous-leishmaniasis
5. National Institutes of Health. Miltefosine for Leishmaniasis. 2021. https://pubmed.ncbi.nlm.nih.gov/33412345/

```